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Background: Proteolytic breakdown of the amyloid precursor protein (APP) by secretases is a complex cellular
process that results in formation of neurotoxic Aβ peptides, causative of neurodegeneration in Alzheimer’s disease
(AD). Processing involves monomeric and dimeric forms of APP that traffic through distinct cellular compartments
where the various secretases reside. Amyloidogenic processing is also influenced by modifiers such as sorting
receptor-related protein (SORLA), an inhibitor of APP breakdown and major AD risk factor.
Results: In this study, we developed a multi-compartment model to simulate the complexity of APP processing in
neurons and to accurately describe the effects of SORLA on these processes. Based on dose–response data, our
study concludes that SORLA specifically impairs processing of APP dimers, the preferred secretase substrate. In
addition, SORLA alters the dynamic behavior of β-secretase, the enzyme responsible for the initial step in the
amyloidogenic processing cascade.
Conclusions: Our multi-compartment model represents a major conceptual advance over single-compartment
models previously used to simulate APP processing; and it identified APP dimers and β-secretase as the two distinct
targets of the inhibitory action of SORLA in Alzheimer’s disease.
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The amyloid precursor protein (APP) is a type-1 mem-
brane protein expressed in neurons, which is closely
linked to the etiology and pathology of Alzheimer’s
disease (AD) [1]. APP undergoes two mutually exclu-
sive processing pathways resulting in the formation of
multiple soluble and membrane-associated fragments
from this precursor polypeptide. Of particular rele-
vance to AD is the amyloidogenic pathway whereby
APP is first cleaved by β-secretase and subsequently by
γ-secretase to produce the amyloid-β peptide (Aβ), a
40 to 42 amino acid fragment derived from part of the
extracellular and the transmembrane domains of APP.* Correspondence: willnow@mdc-berlin.de; olaf.wolkenhauer@uni-rostock.de
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reproduction in any medium, provided the orAccording to the amyloid hypothesis, neurotoxic oligo-
mers and senile plaques formed by Aβ cause neuronal
dysfunction and cell loss in AD [2,3]. In the alternative
pathway, APP is first cleaved by α-secretase, instead of
β-secretase, resulting in the destruction of the Aβ pep-
tide sequence in APP (non-amyloidogenic pathway).
Adding to the complexity of APP processing is the
distinct trafficking route of the precursor through
intracellular compartments where the various secre-
tases reside [4,5]. Thus, newly synthesized APP mole-
cules move through the constitutive secretory pathway
from the trans-Golgi network (TGN) to the cell sur-
face where most are subjected to non-amyloidogenic
processing by α-secretase. However, approximately 10%
of the precursors remain intact and internalize from
the cell surface into endosomal compartments where
amyloidogenic processing is initiated by β-secretase
cleavage.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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analysis of factors that influence APP processing and that
may contribute to the elevated Aβ levels seen in patients
with AD. One such modifier is SORLA, a 250-kDa type-1
membrane glycoprotein widely expressed in neurons in
the brain [6,7]. It is a member of a family of mammalian
proteins that share a structural similarity with the vacuolar
protein sorting 10 protein (VPS10p), a yeast sorting recep-
tor that transports carboxypeptidase Y from the TGN to
the vacuole [8]. SORLA is proposed to act as a retention
factor for APP in the TGN, preventing the release of pre-
cursor molecules into the processing pathways. Conse-
quently, over-expression of SORLA in neurons prevents
the targeting of APP from TGN to the cell surface and to
endosomes and reduces the production of Aβ peptides [9-
11]. The importance of SORLA for AD is further sup-
ported by low levels of receptor expression seen in
patients suffering from the disease [12,13].
In a first approach to simulate amyloidogenic proces-
sing in AD, Schmidt and colleagues [14] developed a
single-compartment model to describe APP processing.
While this model had been valuable to establish the kin-
etics of amyloidogenic processing and the quantitative
contribution of SORLA to this pathway, this single-
compartment model fell short of accurately describing
the complexity of APP processing in cells. It remained
unclear to what extent SORLA may affect APP mono-
mer versus dimer processing and in what compartment
of the cell its activity may be most relevant. Also, a pos-
sible influence of SORLA on the dynamics of β-secretase
remained unclear. Such an effect had been postulated
previously based on studies in cultured cells [15].
To answer these questions, we established a multi-
compartment model that represents APP processing in
both its monomeric and dimeric forms. The formal-
ism of this model is developed to integrate experi-
mental evidences from previous biochemical and cell
biological studies [9-11,13,15-17]. We combined our
multi-compartment model with the recent dose–re-
sponse data of APP and soluble APP products by
Schmidt and colleagues [14]. The data were used to
estimate the parameter values of our model. Using
our multi-compartment model, we (i) established the
activity distribution of APP in various compartments,
and (ii) traced the activity distribution of APP, α-
secretase, β-secretase and SORLA in the monomeric
and dimeric processing of APP. Our simulation results
showed that the decrease in total APP processing is
primarily due to the influence of SORLA on APP
dimer processing. Moreover, the simulations of our
multi-compartment model demonstrated how SORLA
alters the dynamical behavior of β-secretase, providing
new insights into the mechanism of action of this im-
portant AD risk factor.Results and discussion
Multi-compartmental modeling of APP processing in the
presence or absence of SORLA
Probably more than any other major disease entity, AD
is a pathological processes influenced by subtle quantita-
tive changes in protein concentration and activity. Thus,
common approaches in experimental AD research, using
protein overexpression or gene-inactivation, are inad-
equate to study the effects of incremental changes in tar-
get protein levels on risk of neurodegeneration.
In our previous study [14], we have undertaken the
first attempt to approach risk factors in AD through
quantitative modeling. To do so, we have simulated the
quantitative contribution of SORLA to proteolytic pro-
cessing of APP, a central pathway in AD. We have
chosen SORLA as a target for simulation because it
represents one of the major genetic risk factors in AD.
More importantly, solid experimental evidence had
established the molecular mechanism of SORLA action,
acting as an intracellular sorting receptor for APP that
prevents proteolytic breakdown of the precursor protein
into neurotoxic Aβ peptides. In [14], we have been able
mathematically confirm hypotheses, derived from prior
experimental work. In particular, we have confirmed the
strict linear relationship between SORLA concentrations
and efficiency of APP processing, and we have uncov-
ered the ability of SORLA to prevent dimerization of
APP, preventing the formation of high-affinity substrates
for secretases.
While our initial study has been met with great enthu-
siasm in the field, it clearly falls short of addressing
major aspects of SORLA activity in the cell biology of
AD. Thus, for sake of simplification, our earlier study
assumed a single-compartment model for simulation of
the affects of SORLA levels on APP processing rates.
Accordingly, it ignores the fact that APP follows a com-
plex intracellular trafficking pathway whereby this pro-
tein moves between the TGN, cell surface, and
endosomes where the various interacting proteins reside.
In fact, it has the ability to show how SORLA affects
APP transport between various cell compartments in
neurons that initially sparked interest in this protein.
For the present work, a single-compartment model,
describing the influence of SORLA in APP processing
[14], was extended into a multi-compartmental model.
The extended model addresses the important aspect of
the cell biology of SORLA by assuming a three-
compartment model that is based on experimental data.
The biochemical network illustrating this multi-
compartmental model can be found in Figure 1. The no-
tation that is used in this network is described in
Additional file 1: Table S1.
It is likely that there are many other proteins contrib-
ute to the processing of APP and the generation of
Figure 1 Biochemical network of a multi-compartmental model describing the influence of SORLA in APP processing. The three main
yellow compartments in the network are the trans-Golgi network (TGN), the cell surface and the endosomes. Each compartment is subdivided
into two subcompartments: a red subcompartment for APP monomer processing and a green one for dimer processing. The monomeric forms
of APP, SORLA, α-secretase, and β-secretase, within the two subcompartments, are annotated differently: APPG1, SORLAG1, α1, and β1 for monomer
processing, and APPG2, SORLAG2, α2, and β2 for dimer processing. Moreover, APPG2, α2, and β2 undergo dimerization before the start of APP
processing. In the TGN, SORLAG1 binds to APPG1 in red subcompartment while SORLAG2 to APPG2 in the green subcompartment. At the cell
surface, APPCS1 and APPCS2d are cleaved by α1 and α2d producing soluble fragments encompassing the extracellular domain of APP. These
fragments are called soluble (s) sAPPα1 and sAPPα2, respectively. In addition, α-secretase cleavage produces a membrane-associated fragment
containing the membrane anchor and the cytoplasmic tail, denoted C83. In the endosomes, APP molecules that escaped cleavage by α-secretase
(APPE1 and APPE2d) are cleaved by β1 and β2d. Cleavage results in production of the soluble fragments of the extracellular APP domain (sAPPβ1 and
sAPPβ2) and in the membrane-tethered fragments C991 and C992d. C99 includes the Aβ peptide sequence and represents the substrate for γ-
secretase cleavage. The diagram was produced with Cell Designer 4.0 [18,19].
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AD risk factors, the mechanism of action for SORLA
has been established in numerous studies in cell cul-
tures, in animal models, and even in patients providing a
solid base for theoretical simulations. In particular, we
have specifically addressed the caveat that this model fo-
cuses on pathways related to SORLA action, and that
further studies will be required to sequentially add more
risk factors to this model. Such approaches will require a
profound understanding of the function of such risk fac-
tors; - an endeavor that clearly exceeds the scope of the
present manuscript.
The choice of the compartments considered in Figure 1
was based on the different locations where APP was
shown to interact with SORLA, with α-, and with β-
secretases. The corresponding three compartments are
the TGN, the cell surface and the endosomes [9,15,20],
respectively. Note that the transport of APP among
these compartments indirectly interconnects these three
compartments to one another. As SORLA affects the
initial cleavage of APP by α- and β-secretases [11], the
rate limiting steps that determine the extent of amyloi-
dogenic processing, further processing steps involving γ-
secretase were not included in this model.
In order to accommodate the monomeric and dimeric
forms of APP, each compartment was further divided into
two subcompartments (Figure 1): a “red” subcompartmentfor APP monomer processing and a “green” one for APP
dimer processing. Notice that the monomeric forms of
APP, SORLA, α-secretase, and β-secretase, within the
two subcompartments, were annotated differently:
APPG1, SORLAG1, α1, and β1 for monomer processing,
and APPG2, SORLAG2, α2, and β2 for dimer proces-
sing. Even so, the components from the two subcom-
partments were linked to each other via APPinit, αinit,
and βinit. Moreover, APPG2, α2, and β2 undergo
dimerization before the beginning of APP dimer pro-
cessing. That is, two APPG2, α2, and β2 monomers
dimerize in order to give their corresponding dimeric
forms. Conversely, these dimers can dissociate to gen-
erate their respective monomers. Note that subscript
‘1’ was assigned to the reactants and products in
monomer processing while subscript ‘2’ for those in
dimer processing. In addition, we used subscripts ‘G’,
‘CS’, and ‘E’ for APP in TGN, at the cell surface and
in the endosomes, respectively.
Up to this point, we had described the different forms
of APP, α-secretase, and β-secretase in the diverse com-
partments, prior to the beginning of APP processing. Be-
cause SORLA interacts with APP in a 1:1 stochiometric
complex [9,16], the model described how SORLA strictly
interacts with APP-monomers (but not dimers) to form
an APP-SORLA complex. Consequently, this interaction
is responsible for the diminished amount of APP-
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ported from the TGN to the cell surface. This inter-
action decreases the amount of APP-monomers
(APPCS1) and APP-dimers (APPCS2d) ending up in the
endosomes as APPE1 and APPE2d. Moreover, in order to
determine whether SORLA will have a similar influence
on the monomer and dimer processing, the binding af-
finity assigned to APPG1-SORLAG1 in monomer proces-
sing is different to that of APPG2-SORLAG2 in dimer
processing.
After the interaction of SORLA and APP in the TGN,
the remaining APPG1 and APPG2d are transported to the
cell surface where APP processing begins within the
non-amyloidogenic pathway. Then, a small part of
APPCS1 and APPCS2d, which is not cleaved by α-secre-
tase, are further transported from the cell surface to the
endosomes, where the amyloidogenic pathway takes
over. Notably, the interaction of APP and α-secretase at
the cell surface leads to the formation of non-
amyloidogenic products like sAPPα and C83; whereas
the interaction of APP and β-secretase in the endosomes
yields to the amyloidogenic products such as sAPPβ and
C99. Our model was established in such a way that the
dimeric form of secretases act only on the dimeric form
of APP and the monomeric form of secretases act only
on the monomeric form of APP.
The biochemical network (Figure 1) that we estab-
lished, was translated into a system of ordinary differen-
tial equations (ODEs), describing temporal changes of
molecular numbers for the network components as a
function of interaction and cleavage processes. The
model equations, their reduction, and a series of steps
involved in model simulations are presented in the
Materials and Methods section.
Decrease in total amounts of sAPP products is mainly due
to the influence of SORLA in dimer processing
With the multi-compartmental model, we showed in
Figure 2 the corresponding model simulations for vari-
ous APP products, namely, the products produced in
monomer, in dimer, and in both processing pathways.
The simulations of the parameterized mathematical
model are in good agreement with recent experimental
data by Schmidt and colleagues [14] (Figure 2A-D).
In the absence of SORLA, the sigmoidal curve that is char-
acteristic for products produced in dimer processing (green
lines in Figure 2A and B) has a strong impact on the sum of
the products produced in monomer and in dimer processing
pathways (black lines in Figure 2A and B). As such, it very
well describes the experimental data sets for sAPPα and
sAPPβ (black dots in Figure 2A and B, respectively).
Surprisingly, in the presence of SORLA, one observes
from the simulations a significant decrease in the pro-
ducts produced in dimer processing (green lines inFigure 2C and D) as compared to those in monomer
processing (red lines in Figure 2C and D). In particular,
the analysis showed that at a high level of SORLA activ-
ity (i.e. 100% of SORLATot where SORLATot equals 2.43
x 105 fmol), there is obviously more APP bound to
SORLA in dimer processing (Figure 3B) than in mono-
mer processing (Figure 3A).
Taken together, our simulations shown in Figure 2 and
Figure 3, strongly supported the hypothesis whereby
SORLA prevents oligomerization of APP, thereby having
a bigger impact on the products produced in dimer pro-
cessing than in monomer processing.
Intermediate levels of SORLA
Up to this point, we only showed simulations of our
model in the two most extreme scenarios: with no
(Figure 2A and B) or high levels of SORLA activity
(Figure 2C and D). However, subtle alterations of
SORLA concentration are likely to be more relevant for
the determination of its influence in APP processing
pathways. Accordingly, we adapted our multi-
compartment model to intermediate concentrations of
SORLA. As shown in Figures 4, 5, 6 and 7 the simula-
tions are all in dependence of three intermediate SORLA
expression levels, namely, 3%, 12%, and 30% of
SORLATot.
Remarkably, we observed in Figure 4 that the simula-
tions in dependence of the three intermediate SORLA
expression levels are either “spread” (as in Figure 4A and
Figure 4D) or “clustered” (as in Figure 4B and
Figure 4C) into the two most extreme scenarios of
SORLA concentration. This came as a surprised because
the dose–response kinetics of total sAPPα production in
dependence of the intermediate SORLA expression
levels (Figure 4A) is expected to be “clustered” like that
of sAPPβ (Figure 4B). Likewise in the case of the amount
of APP bound to SORLA in monomer (Figure 4C) and
in dimer processing (Figure 4D). We say that the simula-
tions are “clustered” when
XY  X100%  X0%ð Þ⋅Y þ X0%
where Y= {3%, 12%, 30%}, and X denotes the amount of
concentration at a given percentage value of SORLATot
that is specified by its subscript. Otherwise, we say that
the simulations are “spread”.
Next, we investigated what leads to the observation
made in Figure 4, in dependence of the intermediate
SORLA expression levels.
SORLA indirectly affects the dynamical behavior of the β-
secretase but not that of α-secretase
First, we analyzed the simulations of the influence of
intermediate levels of SORLA on APP processing on the
Figure 2 Simulation results of the sAPPα and sAPPβ end products. Simulation results of our multi-compartmental model (lines) for the
various APP products are shown together with the actual data points obtained in biochemical experiments by Schmidt and colleagues [14]. The
total amount of products (black line) is the sum of the products produced in monomer (red line) and in dimer processing (green line) pathways.
In the absence of SORLA, the products produced in the dimer processing pathways more closely resemble the total amount of sAPPα (A) and
sAPPβ (B). With SORLA, the amounts of sAPPα and sAPPβ that are produced in dimer processing are significantly reduced as compared to those
in monomer processing (C, D).
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(Figure 5G-L) concentration. In Figure 5, the term
“used” refers to the complex formation of the secretases
and APP, while the term “free” refers to the secretases
that are not bound in a complex.
The total amount of α-secretase and the total amount of
β-secretase were assumed to be constant (depicted by the
black lines in Figure 5E-F and Figure 5K-L, respectively).
Due to the conservation law assumption, the total amountFigure 3 Complex formation of APP-SORLA in monomer and in dime
processing on the complex formation of APP-SORLA in monomer (A) and
in dimer processing (B) than in monomer processing (A).of each secretase in each subcompartment is conserved
(i.e. αmonomer and βmonomer depicted by red lines in
Figure 5F and Figure 5L; αdimer and βdimer depicted by
green lines in Figure 5F and Figure 5L). Consequently, the
total amount of each secretase in the whole system was
thus also conserved (αTot and βTot shown by the black
lines in Figure 5E-F and Figure 5K-L, respectively).
The simulations of the influence of intermediate levels
of SORLA on APP processing on the amount of α-r processing. Simulations of the influence of SORLA on APP
in dimer (B) processing are shown. There is more APP bound to SORLA
Figure 4 APP processing at intermediate levels of SORLA. Simulations of the influence of intermediate levels of SORLA on APP processing
into the total amount of sAPPα (A) and total amount of sAPPβ (B), and on the complex formation of APP-SORLA in monomer (C) and in dimer
(D) processing are shown. They are simulated in different intermediate levels of SORLA: from without SORLA, to 3%, 12%, 30%, and 100% of
SORLATot (where SORLATot = 2.43 x 10
5 fmol).
Lao et al. BMC Systems Biology 2012, 6:74 Page 6 of 16
http://www.biomedcentral.com/1752-0509/6/74secretase (Figure 5A-F) concentration showed that (i)
there are more α-secretases that were used (Figure 5C)
than left free (Figure 5A) in monomer processing, (ii)
there are more α-secretases that are left free (Figure 5B)
than used (Figure 5D) in the dimer processing, (iii) the
total amount of α-secretase that is free and used (blue
and orange lines in Figure 5E, respectively) is dominated
by the corresponding amount of α-secretase concentra-
tion in dimer (Figure 5B) and in monomer processing
(Figure 5C), (iv) SORLA influences the amount of α-
secretase concentration in dimer processing (Figure 5B
and 5D), but not those in monomer processing
(Figure 5A and 5C), and (v) its simulations in depend-
ence of the three intermediate SORLA expression levels
(Figure 5D) is consistent to that of dose–response kinet-
ics of total sAPPα production (Figure 4A).
The significant difference in the free (Figure 5B) and
used (Figure 5D) amounts of α-secretase in dimer proces-
sing is a consequence of the large amount of α-secretase
used in monomer processing (shown in Figure 5C). As the
total amount of the APP concentration increases (from 0nM to 400 nM), the amount of α-secretase, free in dimer
processing, (Figure 5B) decreases, while the amount of α-
secretase used in monomer processing (Figure 5C)
increases. As the amount of SORLA concentration
increases, the curves representing the secretases move
from solid to dashed lines. SORLA does affect α-secretase
in dimer processing (Figure 5B and 5D): those used in
dimer processing decreases (Figure 5D), while those that
are free in dimer processing increases (Figure 5B). In the
later figure, the increase is not obvious because the
amount of change is so small as compared to the concen-
tration values of α-secretase.
As for the influence of intermediate levels of SORLA
on APP processing on the amount of β-secretase
(Figure 5G-L) concentration, the simulations showed
that (i) there are more β-secretases that are left free
(Figure 5G) than used (Figure 5I) in monomer proces-
sing, (ii) SORLA has no influence on β-secretase in
monomer processing (Figure 5G and Figure 5I), (iii)
SORLA alters the dynamical behaviors of β-secretase in
dimer processing (Figure 5H and Figure 5J), (iv) the total
Figure 5 Concentration values of the secretases at intermediate levels of SORLA. Simulations of the influence of intermediate levels of
SORLA on APP processing on the amount of α-secretase (A-F) and β-secretase (G-L) concentration. The term “used” refers to the complex
formation of the secretases and APP, while the term “free” refers to the secretases that are not bound in a complex. There are five intermediate
levels of SORLA, namely, 0% (solid line), 3%, 12%, 30%, and 100% (dashed line) of SORLATot (where SORLATot = 2.43 x 10
5 fmol). When there is
only solid line in a plot, it is because solid and dashed lines are superimposed. Starting from the first column, there shows the amount of α- (A)
and β-secretase (G) that is free in monomer processing. In the second column, it shows the amount of α- (B) and β-secretase (H) that is free in
dimer processing. The amount of α- (C) and β-secretase (I) used in monomer processing are shown in the third column, whereas those used in
dimer processing (D, J) are shown in the fourth column. In the fifth column, there shows the total amount of α- (E) and β-secretase (K) that is
free (blue line) and used (orange line) in the system. Lastly, there is the total amount of α- (F) and β-secretase (L) in monomer (blue line) and in
dimer (orange line) processing of the system. The black lines in (E, F) and in (K, L) are the estimated total amount of α-and β-secretase,
respectively. In particular, the black line in (E, K) represents the sum of the secretase concentration depicted by the blue and orange lines, while
the one in (F, L) indicates the sum of the secretase concentration depicted by the red and green lines. Notice that the solid and dashed lines for
both blue and orange colors deviates in (K). This, however, is not the case in (E).
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ange lines in Figure 5K, respectively) is dominated by
the amount of β-secretase concentration in dimer pro-
cessing (Figure 5H and Figure 5J, correspondingly), and
(v) its simulations in dependence of the three intermedi-
ate SORLA expression levels (Figure 5H and Figure 5J)
is consistent to that of dose–response kinetics of total
sAPPβ production (Figure 4B). The curves for beta-
secretase with SORLA (dashed lines in Figure 5H) are
greater in values as compared to those without SORLA
(solid line in Figure 5H), as a consequence of SORLA’s
influence on beta-secretase that is used in dimer proces-
sing (Figure 5J).
When a comparison is made between the total amount
of α- and β-secretase concentration that is free (blue lines
in Figure 5E and Figure 5K) and used (orange lines in
Figure 5E and Figure 5K) in dependence of the three inter-
mediate SORLA expression levels, we observed that the
total amount of β-secretase concentration for both free
and used deviated (Figure 5K), which was not the case for
α-secretase (Figure 5E). This observation suggested that
SORLA is indirectly affecting the dynamics of β-secretase
but not that of α-secretase. This result supports the hy-
pothesis presented by Schmidt el al. [14]: “the global–local
estimation of the parameter values in the model suggested
a yet unidentified biological process whereby SORLA
might indirectly affect the β-secretase, but not with the α-secretase”. The present result therefore clarifies what was
unidentified in our previous study [14].
With SORLA concentration greater than the estimated
total amount of SORLA concentration (i.e. SORLATot =
2.43 x 105 fmol), we arrived at Figure S1 shown in Add-
itional file 1: Figures S1D and S1J show that for a very
large amount of SORLATot (greater than 1 x SORLATot
for α-secretase and greater than 10 x SORLATot for β-
secretase), the amount of α- and β-secretase are barely
“used”. Consequently, the amount of α- (Figure B) and
β-secretase (Figure H) are all “free” in dimer processing,
and there will be no sAPP products produced in dimer
processing.
SORLA is more influential in dimer processing than in
monomer processing
We also investigated the amount of APP concentrations
that is either free or used, in monomer or in dimer pro-
cessing, and which is in the TGN, at the cell surface or
in the endosomes (Figure 6). The term “used” refers to
the complex formation of (i) APP and SORLA in the
TGN, (ii) APP and α-secretase at the cell surface, and
(iii) APP and β-secretase in the endosomes. Wherein,
the term “free” refers to the APP that is not bound in
the respective compartments.
First, we showed the simulations of the amount of APP
concentrations that is free or used in monomer and in
Figure 6 Distribution of free and used APP within monomer and dimer processing in each compartment. Simulations of the influence of
intermediate levels of SORLA on APP processing into the amounts of APP concentrations in the TGN (A-E), at the cell surface (F-I), in the
endosomes (J-M), and in all the three compartments (N-Q). The term “used” refers to the complex formation of (i) APP and SORLA in the TGN, (ii)
APP and α-secretase at the cell surface, and (iii) APP and β-secretase in the endosomes. Wherein, the term “free” refers to the APP that is not
bound in the respective compartments. There are five intermediate levels of SORLA, namely, 0% (solid line), 3%, 12%, 30%, and 100% (dashed
line) of SORLATot (where SORLATot = 2.43 x 10
5 fmol). If the dashed line is not seen in a plot, it is because the solid and dashed lines are
superimposed. In the first column, there shows the amount of initial APP concentrations that are left free from the monomer and dimer
processing (A). Next, in the second and third columns, the amounts of APP concentrations that are free and used in monomer processing are
shown, respectively. Then, in the last two columns, the amounts of APP concentrations that are free and used in dimer processing are also given.
Notice that SORLA has minimal or no influence on APP in monomer processing (2nd and 3rd columns); conversely, SORLA shows strong
influence on APP in dimer processing (last two columns).
Lao et al. BMC Systems Biology 2012, 6:74 Page 8 of 16
http://www.biomedcentral.com/1752-0509/6/74dimer processing. The simulations under dimer processing
showed that the amount of APP concentrations that is free
or used in each compartment were significantly affected
by the presence of SORLA (last two columns of Figure 6:
Figure 6D-E, Figure 6H-I, Figure 6L-M, and Figure 6P-Q),
as compared to those under monomer processing (first
three columns of Figure 6: Figure 6A-C, Figure 6F-G,
Figure 6J-K, and Figure 6N-O). In particular, one observes
from the simulations that the amount of APP concentra-
tions that is used to bind with SORLA in dimer processing
of the TGN tremendously increases from 0 M to at most
300 nM (Figure 6E), wherein those in monomer proces-
sing are so small that they can be neglected (Figure 6C).
Consequently, SORLA decreases the amount of APPconcentrations that is free or used at the cell surface and
in the endosomes (Figure 6H-I and Figure 6L-M, respect-
ively). Also, the total amount of APP concentrations in
dimer processing is dominated by the total amount of free
APP in the absence of SORLA and by the total amount of
used APP in the presence of SORLA (depicted by the two
outermost lines in Figure 6P and Figure 6Q).
Next, in each compartment, the simulations for the
total amount of APP concentrations that is free, used, in
monomer processing, or in dimer processing, are shown
in Figure 7. Consistent to our previous observation
(Figure 6), the simulations for total amount of APP con-
centrations in monomer processing for the three differ-
ent compartments (3rd column of Figure 7) were not
Figure 7 Total amount of APP that is free, used, in monomer processing, and in dimer processing in each compartment. Simulations of
the influence of intermediate levels of SORLA on APP processing into the amounts of APP concentrations in the TGN (A-E), at the cell surface (F-
J), in the endosomes (K-O), and in all the three compartments (P-T). There are five intermediate levels of SORLA, namely, 0% (solid line), 3%, 12%,
30%, and 100% (dashed line) of SORLATot (where SORLATot = 2.43 x 10
5 fmol). When there is only solid line in a plot, it is because solid and
dashed lines are superimposed. Note that the term “used” refers to the complex formation of (i) APP and SORLA in the TGN, (ii) APP and α-
secretase at the cell surface, and (iii) APP and β-secretase in the endosomes. Wherein, the term “free” refers to the APP that is not bound in the
respective compartments. The first two columns show the total amount of APP concentrations that is free and used. While in the third and fourth
columns, the total amount of APP concentrations in monomer and in dimer processing are shown, respectively. Each line in the last column has
double meaning: (i) the sum of the corresponding amount of APP concentrations shown in the first two columns, or (ii) the sum of the
respective amount of APP concentrations shown in the third and fourth columns. The plots aligned along the first column show that SORLA
significantly decreases the total amount of free APP concentrations in each compartment. The plots in the second column show that the total
amount of APP concentrations in the TGN increases significantly (B), while unaffecting and minimally decreases those at the cell surface (G) and
in the endosomes (L), respectively. As for the plots in the third column, they show that SORLA has no influence on the total amount of APP
concentrations in monomer processing. Moreover to the plots in the fourth column, it is observed that as the level of SORLA concentration in
dimer processing increases, the total amount of APP concentrations in the TGN also increases (D), while those at the cell surface (I) and in the
endosomes decreases (N).
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were affected by the presence of SORLA (4th column of
Figure 7). Moreover, the simulations, in the first two col-
umns of Figure 7, also showed that the presence of
SORLA in the TGN decreases the total amount of free
APP (Figure 7P), and increases the total amount of used
APP (Figure 7Q). In particular to the total amount of
used APP under the influence of SORLA, it is (i) enor-
mously increased in the TGN (Figure 7B), (ii) notaffected at the cell surface (Figure 7G), and (iii) reduced
by at most half in the endosomes (Figure 7L). Taken to-
gether, the presence of SORLA increases the total
amount of APP concentrations in the TGN (Figure 7E),
and subsequently decreases the total amount of APP
concentrations at the cell surface (Figure 7J) and in the
endosomes (Figure 7O).
The simulations for the total amount of APP concen-
trations in monomer processing (Figure 7R), in dimer
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processing (Figure 7T) show that a conservation law was
assumed for APP in monomer and in dimer processing.
Above all, one observes that there are more APP con-
centrations in dimer processing (Figure 7S) than in
monomer processing (Figure 7R).The spread and clustering of SORLA expression levels
As noted in the subsection, Intermediate levels of
SORLA, the simulations show that SORLA expression
levels are either “spread” (Figure 4A) or “clustered”
(Figure 4B). This is most likely due to the effect of
SORLA on the processing of APP dimer. With respect
to the total amount of APP, the amount of APP concen-
trations (Figure 6I) and α-secretase concentrations
(Figure 5D) that are “used” at the cell surface in dimer
processing “spread”. Considering the relevance of APP
and α-secretase at the cell surface to the production of
sAPPα, the observations thus suggest the “spread”
observed in Figure 4A for sAPPα. Similarly for the “clus-
tering” observed in Figure 4B for sAPPβ, it is a conse-
quence of the “clustering” that is observed on APP
(Figure 6M) and β-secretase (Figure 5J) that are “used”
in the endosome in dimer processing, which are relevant
in producing sAPPβ. Moreover, the change from
“spread” at the cell surface (Figure 4A) to “clustered” in
the endosome (Figure 4B) is probably due to the indirect
influence of SORLA on the dynamical behavior of β-
secretase that is observed in Figure 5.Effects of different SORLA concentrations in switching
sAPPα and sAPPβ from preferred dimer-to-monomer
processing
Lastly, in Figure 8, are given simulations of the influence of
SORLA on APP processing into sAPPα (Figure 8A and
Figure 8C) and sAPPβ (Figure 8B and Figure 8D). The
simulations show that the switch from preferred dimer-to-
monomer processing is observed at 25% of SORLATot for
α-secretase (Figure 8A) and at 3% of SORLATot for β-
secretase (Figure 8B), where SORLATot equals 2.43 x 10
5
fmol. In agreement with the study performed by Schmidt
and colleagues [14] previously, we therefore find that the
switch from cooperative (dimer) to less efficient non-
cooperative (monomer) processing occurs at small amount
of SORLA concentration. Moreover, the end product
obtained from monomer processing dominates the total
amount of end product at 145% of SORLATot for α-
secretase (Figure 8C) and at 150% of SORLATot for β-
secretase (Figure 8D). In connection to what we observed
in Figure 4 for the simulations of the influence of inter-
mediate levels of SORLA on APP processing into sAPPα
(Figure 4A) and sAPPβ (Figure 4B), these two sets of results
(Figure 4 and Figure 8) suggest that SORLA reduces theproducts produced in non-amyloidogenic and amyloido-
genic pathways of APP processing at different rate.
Conclusions
Our multi-compartment model is an extension of the
single-compartment model that was established by
Schmidt and colleagues [14] previously. To our know-
ledge, this is the first multi-compartmental model devel-
oped to analyze APP processing in the context of
Alzheimer’s disease. In addition, our model represents the
regulated trafficking of APP by SORLA through the intra-
cellular compartments, which critically affects amyloido-
genic and non-amyloidogenic processing pathways [20].
Our model was established to answer questions that arose
from a study based on a single-compartment model [14].
The first question that emerged concerned the relative
contributions of SORLA to monomer and in dimer pro-
cessing. In the study conducted by Schmidt and collea-
gues [14], we showed that SORLA influenced the
combined products obtained by monomer and dimer
processing. However, limited by the structure of the
single-compartment model, we were not able to investi-
gate the relative contribution of SORLA in monomer
and in dimer processing. Herein, using our multi-
compartment model, we showed that the decrease in
total amounts of sAPPα and sAPPβ is mainly due to the
influence of SORLA in dimer processing. This observa-
tion confirms previous hypothesis that SORLA, prevent
oligomerization of APP, eliminating the preferred sub-
strates for secretases.
The second question was how does SORLA affect the
dynamics of β-secretase? In the study conducted by
Schmidt and colleagues [14], it was suggested that there
is an indirect effect of the SORLA receptor on the β-
secretase, which contributes to the regulation of amyloi-
dogenic processing in the context of an intact cell. How-
ever, in order for the single-compartment model to
closely resemble the experimental data, the model
required a local parameter estimate for β-secretase activ-
ity in the presence or absence of SORLA. Through our
multi-compartment model, where all parameters are
estimated globally, we now confirmed that SORLA
affects the interaction between APP and β-secretase, but
not that of APP with α-secretase. A previous study sug-
gested that SORLA directly interacts with β-secretase,
preventing access of the enzyme to its substrate APP
[15]. While our simulations confirm an important influ-
ence of SORLA on β-secretase, this influence may also
be indirect, for example by effecting trafficking of cofac-
tors essential for enzyme activity. An indirect effect of
SORLA is in line with findings that the receptor does
not impair β-secretase activity in cell-free assays [14].
In addition, we investigated the regulated trafficking of
APP by SORLA in monomer and dimer processing,
Figure 8 Switch from preferred dimer-to-monomer processing. Simulations of the influence of SORLA on APP processing into sAPPα (A, C)
and sAPPβ (B, D) are shown (where SORLATot = 2.43 x 105 fmol). Total amount of products produced from both processing (black line) as well as
the products produced from dimer (green line) and monomer (red line) processing are indicated for each simulation. A switch from preferred
dimer-to-monomer processing is seen at 25% of SORLATot for α-secretase (A) and at 3% of SORLATot for β-secretase (B). The amount of product
obtained from ‘red’ monomer is greater than that of ‘green’ dimer is observed at 145% of SORLATot for α-secretase (C) and at 150% of SORLATot
for β-secretase (D).
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TGN, cell surface, and endosomes. Simulations of our
multi-compartment model showed that SORLA increases
the total amount of APP concentrations in the TGN
(Figure 7E) and subsequently decreases the total amount
of APP at the cell surface (Figure 7J) and endosomes
(Figure 7O). In agreement with Andersen and Willnow
[21], this result suggests that an over-expression of
SORLA prevents the localization of APP from the TGN to
the cell surface and to the endosomes, whereby an over-
expression of SORLA decreases the products produced in
the amyloidogenic and non-amyloidogenic pathways of
APP processing. Furthermore, our study confirmed that
SORLA is more influential in dimer than in monomer
processing. This observation is in line with our previous
model that APP dimers represent the preferred substrate
for α- and β-secretase as they enable cooperativity in sub-
strate binding [14]. Taken together, data obtained both in
single and in multi-compartment models strongly sug-
gested that depletion of APP dimer processing represents
a major molecular mechanism in the pathology of Alzhei-
mer’s disease.
Our multi-compartment model was used to simulate
pathological situations involving APP under different
level of SORLA concentration. Our model can also be
used as a kinetic-dynamic model to study the effects ofSORLA on α- and β- secretase. Moreover, we observed
that as the amount of SORLA concentration increases,
there is a relatively large decrease in the production
rate of sAPPα as compared to that of sAPPβ (Figure 4
and Figure 8).
Using this refined model together with the chosen set
of estimated parameter values (shown in Additional file
1: Table S4), our results suggest the following biological
implications of SORLA: (1) Decrease in total amounts of
sAPP products is mainly due to the large amount of
SORLA concentration in dimer processing (2.43 x 105
fmol), and not to the small amount of SORLA concen-
tration in monomer processing (1.23 x 101 fmol). (2)
SORLA indirectly affects the dynamical behavior of the
β-secretase but not that of α-secretase. The receptor tar-
gets β-secretase, the enzyme responsible for initial amy-
loidogenic cleavage. This finding represents a major
conceptual advance in our understanding of the complex
processes in APP processing and supports initial bio-
chemical data that SORLA can bind to β-secretase [15].
(3) SORLA is more influential in dimer processing that
in monomer processing, which confirmed our initial hy-
pothesis that blockade of APP dimerization is an import-
ant aspect of SORLA action on AD.
In future studies, we will extend this model by including
additional cleavage activity by γ-secretase in monomer
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leads to the formation of Aβ peptides, which is the main
pathology of Alzheimer’s disease. The ultimate goal is
therefore to establish a model that will test the potential




Based on the biochemical network (Figure 1), we estab-
lished ODEs that describe temporal changes of molecu-
lar numbers for the network components as a function
of interaction and cleavage processes, such that the
changes with large numbers of molecules can be
assumed to be smooth. The complete formulation of the
model, realized as set of ODEs, can be found in the
Additional file 1. Also, the notations used in the equa-
tions are described in Additional file 1: Table S2.
Recall that the components in our multi-compartment
model, separated by the three different compartments and
two different subcompartments, are annotated differently.
Distinctly labeling them allows differentiation and com-
parison of the results generated from these multi-com-
partment. Consequently, we could distinguish the level of
influence of SORLA between the monomeric and the di-
meric form of APP processing, and also determine in
which form of APP processing is SORLA more influential.
Herein, we showed a series of assumptions that
allowed the reduction of the equations.
Firstly, we started with the transportation of APP, α-,
and β-secretase among the three compartments and be-
tween the two subcompartments. Recall that the (i)
APP-monomers and APP-dimers are transported from
the TGN to the cell surface, and are then further trans-
ported to the endosomes, (ii) monomeric forms of APP,
SORLA, α-secretase, and β-secretase, within the two
subcompartments, are annotated differently, and (iii)
components within the two subcompartments are linked
to each other via APPinit, αinit, and βinit. These properties











where the second reactant is assumed to be in quasi-
equilibrium with the first reactant. Without loss ofgenerality, the concentration of the second reactant is













where KG1 ¼ kg1=kg1, KG2 ¼ kg2=kg2, KCS1 ¼ kcs1=kcs1,
KCS2 ¼ kcs2=kcs2, KC1 ¼ kc1=kc1, KC2 ¼ kc2=kc2, KB1 ¼












the ratio of the association constant is taken into consid-
eration. This assumption permits the two reactants to be






where KE1 ¼ ke1=ke1 and KE2 ¼ ke2=ke2.
Secondly, the monomeric forms of APP, α-, and β-
secretase in dimer processing undergo dimerization. In
other words, two monomeric forms of APP, α-, or β-
secretase are dimerized, and a dimeric form of APP, α-,

















As we took into account the association constant of
each reaction above, it allows us to have the following






where KG3 ¼ kg3=kg3 , KC3 ¼ kc3=kc3 , and KB3 ¼
kb3=kb3.
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scribe the relationship of APP, α-, or β-secretase, which
are defined in the three different compartments.
Thirdly, at the cell surface, APP interacts with α-










CAPPCS2dα2d!k61 2⋅sAPPα2 þ C832d þ α2d











CAPPE2dβ2d!k41 2⋅sAPPβ2 þ C992d þ β2d
For the ODEs of the complexes above (found in Add-
itional file 1), a quasi-steady state can be assumed. This







where KMα1 ¼ k5 þ k6ð Þ=k5 , KMα2d ¼ k51 þ k61ð Þ=k51 ,
KMβ1 ¼ k3 þ k4ð Þ=k3 , and KMβ2d ¼ k31 þ k41ð Þ=k31 .
These equations for the complexes are turned into the
ODEs that describe the formation of the sAPP products:
the ODEs of the sAPP products in the monomeric form











whereas those in the dimeric form of APP processing


























Fourthly, recall that APPG1 binds to SORLAG1 with a
binding affinity of KS1 in monomer processing, whereas
APPG2 to SORLAG2 with a different binding affinity KS2












We then took into consideration the rapid-equilibrium
assumption for the CAPPG1SORLAG1 and CAPPG2SORLAG2





Lastly, the ODEs include conservation laws for the
molecule numbers of enzymes and substrates. Herein,
we took into account Equations (1) to (4) and (8) that
are shown previously. For α-secretase and β-secretase,
conservation law assumption leads to
αTot ¼ αinit þ αmonomer þ αdimer




αmonomer ¼ α1 þ CAPPCS1α1
αdimer ¼ α2 þ α2d þ CAPPCS2dα2d
βmonomer ¼ β1 þ CAPPE1β1




SORLATot ¼ SORLAmonomer þ SORLAdimer ð11Þ
where
SORLAmonomer ¼ SORLAG1 þ CAPPG1SORLAG1
SORLA dimer ¼ SORLAG2 þ CAPPG2SORLAG2

ð12Þ
Moreover, the ODEs also include conservation of the
APP substrate. This leads to the following representation:
APPTot ¼ APPinit þ APPmonomer þ APPdimer ð13Þ
where
APPmonomer APPinit ; αinit ; βinit
  ¼ APPG1 þ APPCS1 þ APPE1
þCAPPCS1α1 þ CAPPE1β1
APPdimer APPinit; αinit ; βinit
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APPmonomer APPG1; α1; β1ð Þ ¼ APPG1 þ APPCS1 þ APPE1þ
CAPPCS1α1 þ CAPPE1β1 þ CAPPG1SORLAG1
APPdimer APPG2; α2; β2ð Þ ¼ APPG2 þ APPG2d þ APPCS2d þ APPE2dþ




in the presence of SORLA.
Below, we discuss in more detail the properties be-
hind equations (9)-(15): (I) each conserved equation
is a function of free reactant and of reactant bound
in the complexes. Note that the reactant can be the
APP, SORLA, α-, or β-secretase. (II) Each ReactantTot
function is represented differently in the presence and
in the absence of SORLA. In particular, each Reac-
tantTot function without SORLA is transcribed as
function of APPinit, αinit, and βinit, whereas those with
SORLA are transcribed as function of APPG1, APPG2,
α1, α2, β1, and β2. (III) The amount of the Reactantinit
in each ReactantTot with SORLA is set to be the same
as that calculated from the corresponding ReactantTot
without SORLA. (IV) Similarly, the total amount of
Reactantmonomer and Reactantdimer in each ReactantTot
with SORLA are equivalent to those calculated from
the corresponding ReactantTot without SORLA. (V)
The amount of SORLATot, αTot, and βTot are assumed
to be constant for different amount of APPTot con-
centration. This assumption is based on the experi-
mental design applied on the series of dose–response
data [14] that are used in this study. (VI) Without
loss of generality, SORLAmonomer and SORLAdimer are
also assumed to be constant for different amount of
APPTot concentration.
The properties defined above are, in particular, neces-
sary and important. Without those properties, the pres-
ence of SORLA in monomer processing will not only
affect the monomeric form of APP processing, it will
also indirectly influence the dimeric form of APP pro-
cessing, and vice versa. As such, it defeated the main
purpose of this study, which is to differentiate the level




















The development of the model described in the previous
section reduced the number of free parameters from 77
to 27. The reduced number of parameter values of the
model were estimated by nonlinear optimization such
that the model simulations fit four biological independ-
ent dose–response series without SORLA (a total of
N= 64 experimental data points) and five biological in-
dependent dose–response series with SORLA (also a
total of N=64 experimental data points). We looked for a
set of parameter values that minimizes the weighted least
squares function of APPTot with SORLA, and sAṖPαTot and
sAṖPβTot in regardless of SORLA (Equation (7)). On ac-
count of the different orders of magnitude of the experi-
mental values of APP, sAPPα, and sAPPβ, weights were
assigned such that the influence of each data set in the








































where the superscript ‘E’ and the subscript ‘S’ denotes ex-
perimental data points and the influence of SORLA, re-
spectively. The goodness of fit was quantified by
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spective weight:
We used the lsqnonlin and fzero functions in the
MATLAB optimization toolbox [22] to estimate un-
known parameter values. The estimation of parameter
values was performed by the steps elaborated in Add-
itional file 1: Table S3.
We performed 500 global estimates, satisfying the con-
dition that all parameter values are positive. Note that
none of the parameter values are taken from the litera-
ture due to the differences in the experimental methods
applied. Most kinetic data available in the literature on
α/β-secretase activity were obtained in cell free assays
with purified enzyme and artificial peptide substrate.
This is in contrast to our model that relies in quantita-
tive data obtained on APP processing in intact cell. Fur-
thermore, the parameter values estimated for our multi-
compartment model are expected to differ from that of
the single-compartment model by Schmidt and collea-
gues [14]. Out of the 500 simulation runs, we took the
set of estimated parameter values that has the smallest
residual value, as shown in Additional file 1: Table S4.
Experimental materials and methodology
Details about the protocol and assay procedures of the
experimental data used in this study can be found in the
paper by Schmidt and colleagues [14].
Additional file
Additional file 1: Mathematical Modeling. The complete formulation
of the model, realized as set of ODEs. Table S1 – Variables in the
biochemical network. The table contains the description of the
variables that are used in the different compartments of the biochemical
network (shown in Figure 1). Table S2 – Variables and parameters in
the mathematical model. The table contains the unit and the
description of the variables and parameters used in the mathematical
model. Table S3 – Simulation steps. The steps performed for the
estimation of parameter values are elaborated here. Table S4 -
Estimated parameter values for Figure 2. The table shows a set of
estimated parameter values, which has the lowest residual value out of
500 simulation runs. Figure S1 – Concentration values of the
secretases with higher SORLATot values. The figure shows simulations
of the influence of intermediate levels of SORLA that are greater that the
value of SORLATot, on the amount of α-secretase and β-secretase
concentrations on APP processing.
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